SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Eisenbarth GS. Type I diabetes: a chronic autoimmune disease. N Eng J Med 1986; 314: 13608.
  • 2
    Stiller CR, Dupre J, Gent M et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223: 13627.
  • 3
    Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331: 142836.
  • 4
    Roep BO, Arden SD, De Vries RR et al. T-cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins. Nature 1990; 345: 6324.
  • 5
    Roep BO, Kallan AA, Hazenbos WL et al. T-cell reactivity to 38 kD insulin-secretory-granule protein in patients with recent-onset type 1 diabetes. Lancet 1991; 337: 143941.
  • 6
    Panina-Bordignon P, Lang R, Van Endert PM et al. Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med 1995; 181: 19237.
  • 7
    Baekkeskov S, Aanstoot HJ, Christgau S et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347: 1516.
  • 8
    Rabin DU, Pleasic SM, Shapiro JA et al. Islet cell antigen 512 is a diabetic-specific islet autoantigen related to protein tyrosin phosphateses. J Immunol 1994; 152: 318391.
  • 9
    Dean BM, Pujol-Borrel R, Botazzo GF. Determination of islet cell antibodies by immunofluorescence. Lancet 1982; 2: 13437.
  • 10
    Lan MS, Lu J, Goto Y et al. Molecular cloning and identification of a relation type protein tyrosin phosphatase, IA-2 from human insulinoma. DNA Cell Biol 1994; 13: 50514.
  • 11
    Palmer JP, Asplin CM, Clemons P et al. Insulin antibodies in insulin-dependent diabetes before insulin treatment. Science 1983; 222: 13379.
  • 12
    Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 1997; 7: 72738.
  • 13
    Lenschow DJ, Ho SC, Sattar H et al. Differential effects of anti-B7–1 and anti-B7–2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mice. J Exp Med 1995; 181: 114555.
  • 14
    Moriyama H, Yokono K, Amano K et al. Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/ intercellular adhesion molecule-1 pathway. J Immunol 1996; 157: 373743.
  • 15
    Balasa B, Krahl T, Patstone G et al. CD40 ligand-CD40 interactioins are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997; 159: 46207.
  • 16
    Arens R, Tesselaar K, Baars PA et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 2001; 15: 80112.
  • 17
    Morimoto S, Kanno Y, Tanaka Y et al. CD134L engagement enhances human B cell Ig production. CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J Immunol 2000; 164: 4097104.
  • 18
    Schwab U, Stein H, Gerdes J et al. Production of monoclonal antiboby specific for Hodge and Reed-Sternberg cells of Hodgekin disease and a subset of normal lymphoid cells. Nature 1982; 299: 6571.
  • 19
    Smith CA, Gruss HJ, Davis T et al. CD30 antigen, a marker for Hodgekin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1999; 73: 134960.
  • 20
    Seko Y, Takahashi N, Oshima H et al. Expression of tumour necrosis factor (TNF) receptor/ligand superfamily co-stimulatory molecules CD40, CD30L, CD27L, and OX40L in murine hearts with chronic ongoing myocarditis caused by coxsackie virus B3. J Pathol 1999; 188: 42330.
  • 21
    Shanebeck KD, Maliszewski CR, Kennedy MK et al. Regulation of murine B cell growth and differtiation by CD30 ligand. Eur J Immunol 1995; 25: 214753.
  • 22
    Gruss HJ, Boiani N, Williams DE et al. Pleotropic effects of the CD30 ligand on CD30 expressing cells and lymphoma cell lines. Blood 1994; 83: 204556.
  • 23
    Bowen MA, Olsen KJ, Cheng L et al. Functional effect of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R and induction of homotypic aggregation. J Immunol 1993; 151: 5896906.
  • 24
    Gerli R, Pitzalis C, Bistoni O et al. CD30+ T cells in rheumatoid synovitis. mechanisms of recruitment and functional role. J Immunol 2000; 164: 4399407.
  • 25
    Saraiva M, Smith P, Fallon PG et al. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J Exp Med 2002; 196: 82939.
  • 26
    Kurts C, Carbone FR, Krummel MF et al. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 1999; 398: 3414.
  • 27
    Kurts C, Carbone FR, Krummel MF et al. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 2000; 407: 413.
  • 28
    Seigmund T, Armitage N, Wicker LS et al. Analysis of the mouse CD30 gene; A candidate for the NOD mouse type 1 diabetes locus IDD9. 2 Diabetes 2000; 49: 16126.
  • 29
    Yoneda R, Yokono K, Nagata M et al. CD8 cytotoxic T-cell clone rapidly transfers autoimmune diabetes in very young NOD and MHC class 1- compatible scid mice. Diabetologia 1997; 40: 104452.
  • 30
    Nakayama M, Nagata M, Yasuda H et al. Fas/Fas ligand interactions play an essential role in the initiation of murine autoimmune diabetes. Diabetes 2002; 51: 13917.
  • 31
    Shimozato O, Takeda K, Yagita H et al. Expression of CD30 ligand (CD153) on murine activated T cells. Biochem Biophys Res Commun 1999; 256: 51926.
  • 32
    Caligaris-Cappio F, Bertero MT, Converso M et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with SLE and correlate with disease activity. Clin Exp Rheumatol 1995; 13: 33943.
  • 33
    Gerli R, Muscat C, Bistoni O et al. High level of the soluble form of CD30 molecules in rheumatoid arthritis are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol 1995; 102: 54750.
  • 34
    Okumura M, Hidaka Y, Kuroda S et al. Increased serum concentration of soluble CD30 in patients with Graves’ disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 1997; 82: 175760.
  • 35
    Wicker LS, Leiter EH, Todd JA et al. Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes 1994; 43: 5004.
  • 36
    Serreze DV, Chapman HD, Varnum DS et al. Initiation of autoimmune diabetes in NOD/Lt mice is MHC class I-dependent. J Immunol 1997; 158: 397886.
  • 37
    Wong FS, Visintin I, Wen L et al. CD8 T-cell clones from young nonobese diabetic (NOD) can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med 1996; 183: 6776.
  • 38
    Wong FS, Karttunen J, Dumont C et al. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 1999; 5: 102631.
  • 39
    Opat S, Gaston JS. CD30:CD30L interactions in the immune response. Autoimmunity 2001; 33: 4560.